Camptodactyly Syndrome, Guadalajara Type 3 (CSG3) is a rare genetic disorder characterized by the permanent flexion of the fingers and toes, as well as other skeletal abnormalities. It is caused by a mutation in the gene encoding the protein filamin A, which is involved in the formation of the cytoskeleton. Symptoms of CSG3 include camptodactyly (permanent flexion of the fingers and toes), joint contractures, scoliosis, and short stature. Other features may include facial dysmorphism, intellectual disability, and hearing loss. Treatment is supportive and may include physical therapy, splinting, and orthopedic surgery.

The symptoms of Camptodactyly Syndrome, Guadalajara Type 3 (CSG3) include:

-Flexion contractures of the fingers and toes
-Abnormal curvature of the fingers and toes
-Abnormal joint mobility
-Abnormal joint stability
-Abnormal joint laxity
-Abnormal joint stiffness
-Abnormal joint swelling
-Abnormal joint pain
-Abnormal joint deformity
-Abnormal joint crepitus
-Abnormal joint instability
-Abnormal joint range of motion
-Abnormal joint tenderness
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint instability
-Abnormal joint

Camptodactyly syndrome, Guadalajara type 3 (CGD3) is a rare genetic disorder caused by a mutation in the gene encoding the protein filamin A (FLNA). This mutation results in a decrease in the amount of filamin A protein in the body, which can lead to a variety of physical and neurological symptoms. The most common symptom of CGD3 is camptodactyly, which is a permanent flexion of the fingers and toes. Other symptoms may include joint contractures, scoliosis, facial dysmorphism, intellectual disability, and seizures. The exact cause of the mutation in the FLNA gene is unknown, but it is believed to be inherited in an autosomal dominant manner.

The treatments for Camptodactyly Syndrome, Guadalajara Type 3 (CSGT3) vary depending on the severity of the condition. Generally, treatment focuses on improving range of motion and reducing pain. This may include physical therapy, splinting, and stretching exercises. In more severe cases, surgery may be recommended to correct the deformity. Other treatments may include occupational therapy, orthotics, and bracing. In some cases, medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) may be prescribed to reduce pain and inflammation.

1. Genetic predisposition: Camptodactyly syndrome, Guadalajara type 3 is an autosomal recessive disorder, meaning that it is caused by a mutation in both copies of a gene.

2. Family history: Individuals with a family history of Camptodactyly syndrome, Guadalajara type 3 are at an increased risk of developing the condition.

3. Ethnicity: Camptodactyly syndrome, Guadalajara type 3 is more common in individuals of Mexican descent.

4. Age: Camptodactyly syndrome, Guadalajara type 3 is more likely to occur in children and young adults.

At this time, there is no known cure for Camptodactyly Syndrome, Guadalajara type 3. However, there are medications and treatments that can help manage the symptoms. These include physical therapy, splinting, and medications such as botulinum toxin injections, nonsteroidal anti-inflammatory drugs, and muscle relaxants. Surgery may also be an option for some patients.